English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/122477
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the first dual BACE-1/GSK-3β fragment hits against Alzheimer’s disease

Otros títulosTriazinones as the first dual BACE-1/GSK-3β fragment hits against Alzheimer’s disease
AutorPrati, Federica; Pérez, Daniel I.; Pérez Castillo, Ana ; Martínez, Ana ; Bolognesi, Maria Laura
Palabras claveAlzheimer’s disease
6-amino-3
4-dihydro-1
3,5-triazin-2(1H)-one
Drug design
Multitarget-directed ligands
Multitarget drug discovery
Fecha de publicación14-jul-2015
EditorAmerican Chemical Society
CitaciónACS Chem. Neurosci., Article ASAP
ResumenOne of the main obstacles toward the discovery of effective anti-Alzheimer drugs is the multifactorial nature of its etiopathology. Therefore, the use of multitarget-directed ligands has emerged as particularly suitable. Such ligands, able to modulate different neurodegenerative pathways, for example, amyloid and tau cascades, as well as cognitive and neurogenic functions, are fostered to come. In this respect, we report herein on the first class of BACE-1/GSK-3β dual inhibitors based on a 3,4-dihydro-1,3,5-triazin-2(1H)-one skeleton, whose hit compound 1 showed interesting properties in a preliminary investigation. Notably, compound 2, endowed with well-balanced potencies against the two isolated enzymes (IC50 of 16 and 7 μM against BACE-1 and GSK-3β, respectively), displayed effective neuroprotective and neurogenic activities and no neurotoxicity in cell-based assays. It also showed good brain permeability in a pharmacokinetic assessment in mice. Overall, triazinone derivatives, thanks to the simultaneous modulation of multiple points of the diseased network, might emerge as suitable candidates to be tested in in vivo Alzheimer’s disease models.
Descripción72 p.-7 fig.-2 tab.-4 sch. Prati, Federica et al.
Versión del editorhttp://dx.doi.org/ 10.1021/acschemneuro.5b00121
URIhttp://hdl.handle.net/10261/122477
DOI10.1021/acschemneuro.5b00121
ISSN1948-7193,
E-ISSN1948-7193
Aparece en las colecciones: (CIB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
acs chem. neur._Martínez, Ana_2015(post).pdfPostprint1,78 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.